Baxter Q3 FY2026: sales up 5%, adjusted EPS beats, outlook raised
Baxter beat the adjusted EPS consensus, grew sales 5.0% with every division contributing, and lifted full-year guidance — but adjusted profit still fell 16.0% on a higher tax rate. Read the quarter in two layers: the top line and cash are improving, while the bottom line is propped up by a $253 million debt-extinguishment gain and a still-thin 7.6% GAAP operating margin.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS was $0.57 and adjusted EPS $0.58, ahead of the $0.52 consensus figure. The catch is direction: adjusted EPS fell 16.0% from $0.69 a year ago because the adjusted tax rate jumped to 18.3% from 5.1%. GAAP net income of $294 million also carries a $253 million debt-extinguishment gain worth $0.38 a share, so the headline number is not a clean read on the quarter.
Sales of $2.98 billion rose 5.0% from $2.84 billion a year ago, and management says the increase was 5.0% even after stripping out currency and deal effects. All four divisions grew, led by Advanced Surgery at 12.0% and Care & Connectivity Solutions at 5.0%. Infusion Therapies & Platforms did the heavy lifting at $1.76 billion, or 59.1% of the total.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-03
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.